Condition
Sjogren Disease
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (1)
P 4 (1)
Trial Status
Recruiting2
Withdrawn1
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07041099Phase 1Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
NCT06928142Phase 2Active Not RecruitingPrimary
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT07153276Phase 4Recruiting
TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE
NCT06411639Phase 1WithdrawnPrimary
Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases
Showing all 4 trials